Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 8/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.32 |
| ▸ | STAT6 | P42226 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17473611 | 1.00 | F2 (0.73) | F2ITGB3ITGA2BPLATPRSS1 | |
| Ximelagatran SCHEMBL15908919 | 0.84 | F2 (1.00) | F2ITGB3ITGA2BPLATPRSS1 | |
| Ximelagatran SCHEMBL19065093 | 0.84 | F2 (1.00) | F2ITGB3ITGA2BPLATPRSS1 | |
| Ximelagatran SCHEMBL14509860 | 0.84 | F2 (1.00) | F2ITGB3ITGA2BPLATPRSS1 | |
| Ximelagatran SCHEMBL4845 | 0.84 | F2 (1.00) | F2ITGB3ITGA2BPLATPRSS1 | |
| SCHEMBL8081029 | 0.83 | F2 (0.81) | F2ITGB3ITGA2BPLATPRSS1 | |
| SCHEMBL8088279 | 0.82 | F2 (0.79) | F2ITGB3ITGA2BPLATPRSS1 | |
| Ximelagatran SCHEMBL7222774 | 0.79 | F2 (0.88) | F2ITGB3ITGA2BPLATPRSS1 | |
| SCHEMBL8075938 | 0.74 | F2 (0.68) | F2ITGB3ITGA2BPLATPRSS1 | |
| SCHEMBL8080981 | 0.74 | F2 (0.67) | F2ITGB3ITGA2BPLATPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207282-B2 | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200261386-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-10583104-B2 | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-03-10 | — | — | US | disclosed |
| US-20170189362-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-8795963-B2 | Genetic markers for risk management of atrial fibrillation and stroke | DECODE GENETICS EHF. (IS) | 2014-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207282-B2 | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis | PLAT, PLG, PLAUR | F2 4/4885ITGB3 551/4885ITGA2B 317/4885 |
| US-10583104-B2 | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis | PLAT, PLG, PLAUR | F2 4/4885ITGB3 551/4885ITGA2B 317/4885 |
| US-20170189362-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | F2 4/4885ITGB3 551/4885ITGA2B 317/4885 |
| US-20200261386-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | F2 4/4885ITGB3 551/4885ITGA2B 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.